Matches in UGent Biblio for { <https://biblio.ugent.be/publication/356871#aggregation> ?p ?o. }
Showing items 1 to 39 of
39
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B154575.
- aggregation creator B154576.
- aggregation creator B154577.
- aggregation creator B154578.
- aggregation creator B154579.
- aggregation creator B154580.
- aggregation creator B154581.
- aggregation creator B154582.
- aggregation creator B154583.
- aggregation creator B154584.
- aggregation creator person.
- aggregation date "2006".
- aggregation hasFormat 356871.bibtex.
- aggregation hasFormat 356871.csv.
- aggregation hasFormat 356871.dc.
- aggregation hasFormat 356871.didl.
- aggregation hasFormat 356871.doc.
- aggregation hasFormat 356871.json.
- aggregation hasFormat 356871.mets.
- aggregation hasFormat 356871.mods.
- aggregation hasFormat 356871.rdf.
- aggregation hasFormat 356871.ris.
- aggregation hasFormat 356871.txt.
- aggregation hasFormat 356871.xls.
- aggregation hasFormat 356871.yaml.
- aggregation isPartOf urn:issn:0923-7534.
- aggregation language "eng".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients".
- aggregation abstract "Purpose: A multicentric, phase II study to evaluate the efficacy and safety of the combination paclitaxel and oxaliplatin in patients with platinum-sensitive recurrent ovarian cancer. Patients and methods: Patients received 175 mg/m(2) paclitaxel (over 3 h) followed by 130 mg/m(2) oxaliplatin (over 2 h) every 21 days for up to nine cycles without hydration or primary granulocyte colony-stimulating factor prophylaxis. Patients had to have an Eastern Cooperative Oncology Group performance status of 0-2 and to have received no more than one prior cisplatin- and/or carboplatin-containing chemotherapy regimen with a platinum-progression-free interval >= 6 months. Results: Of the 105 patients enrolled and treated, 98 were eligible. An overall response rate of 81% (79 of 98 patients) (95% confidence interval 71% to 88%) was observed according to RECIST criteria (third party reviewed), and 88% (86 of 98) when this was complemented with CA-125 response. With a median follow up of 43.6 months (range 30.2-64.2) the median progression-free survival was 10.2 months (range 0.3-21.4) and the overall survival 32.4 months. Seven hundred and eight cycles were administered (median seven per patient; range one to nine). A total of 67% of patients experienced National Cancer Institute Common Toxicity Criteria grade 3-4 neutropenia, including 8% with concomitant febrile episode, without treatment-related deaths. Ninety-three per cent of patients experienced neuropathy of grade 1 or more, including 25% with cumulative reversible peripheral neuropathy of grade 3-4. Oxaliplatin doses were reduced in 30 patients due to neurotoxicity. Conclusions: The oxaliplatin/paclitaxel combination can be administered in an outpatient setting every 3 weeks without specific measures. The high level of activity and its duration observed warrants further evaluation of this combination in pretreated platinum-sensitive advanced ovarian cancer patients.".
- aggregation authorList BK386124.
- aggregation endPage "436".
- aggregation issue "3".
- aggregation startPage "429".
- aggregation volume "17".
- aggregation isDescribedBy 356871.
- aggregation similarTo mdj097.
- aggregation similarTo LU-356871.